Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder symptomatically
characterized by resting tremor, rigidity, bradykinesia, and gait impairment. These motor …

Nanotechnology will play a key role in developing new diagnostic and therapeutic tools. …
All of them are relevant to improve current therapy of Parkinson's disease (PD). …

… Described by James Parkinson in 1817, Parkinson’s disease (PD) is the second most
common chronic neurodegenerative disease in the world, affecting over 10 million people, and …

… From a therapeutic perspective, the introduction of levodopa (l-DOPA) in the 1960s … it
continues to be the most effective symptomatic therapy in Parkinsonian disorders [15]. However, the …

… However, Parkinson's disease involves degeneration of non-dopaminergic … for Parkinson's
disease, and also for the motor complications that arise from the use of existing therapies. …

… of Alzheimer's disease and Parkinson's disease and demonstrates the potential of
developing relevant therapeutic strategies based on lipid metabolism as a breakthrough point. …

Parkinson’s disease (PD) is a slow insidious neurological disorder characterized by a loss of
dopaminergic neurons in the midbrain. Although several recent preclinical advances have …

… replacement therapies have long been an attractive prospect for treating Parkinson disease.
… -derived cell transplants in individuals with Parkinson disease have been variable, in part …

Parkinson's disease (PD) is a progressive neurodegenerative disorder in which the degeneration
of dopaminergic neurons projecting from the substantia nigra to the striatum is a key …

… Although levodopa is widely recognized as the most effective therapy for Parkinson disease
(PD), its introduction 5 decades ago was preceded by several years of uncertainty and …